Payment overview · 2025
General Payments
$189.82
10 reported records · 6 companies
Healthcare provider profile · identity verified
Richard E Wheeler, MD
Allopathic & Osteopathic Physicians|Family Medicine · NASHVILLE, GA · NPI 1619954112
Verified facts
What the public records show
CMS Open Payments records show Richard E Wheeler, MD received $189.82 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 24.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.90 | 24.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $43.64 | 23.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.17 | 17.5% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.77 | 15.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.41 | 12.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.93 | 7.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $189.82 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $43.64 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
55 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
113 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 935 | 219 |
| Atorvastatin Calcium | Atorvastatin Calcium | 694 | 170 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 618 | 109 |
| Pantoprazole Sodium | Pantoprazole Sodium | 571 | 145 |
| Lisinopril | Lisinopril | 508 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 502 | 110 |
| Gabapentin | Gabapentin | 481 | 115 |
| Metformin Hcl | Metformin Hcl | 383 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 362 | 73 |
| Tramadol Hcl | Tramadol Hcl | 334 | 81 |
| Furosemide | Furosemide | 317 | 86 |
| Montelukast Sodium | Montelukast Sodium | 317 | 60 |
| Omeprazole | Omeprazole | 311 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 300 | 64 |
| Eliquis | Apixaban | 293 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 287 | 79 |
| Famotidine | Famotidine | 287 | 46 |
| Losartan Potassium | Losartan Potassium | 286 | 86 |
| Potassium Chloride | Potassium Chloride | 282 | 60 |
| Simvastatin | Simvastatin | 275 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 66 |
| Alprazolam | Alprazolam | 235 | 43 |
| Sertraline Hcl | Sertraline Hcl | 217 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 215 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 199 | 53 |
| Trazodone Hcl | Trazodone Hcl | 193 | 43 |
| Pregabalin | Pregabalin | 190 | 41 |
| Meloxicam | Meloxicam | 188 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 49 |
| Mirtazapine | Mirtazapine | 186 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 179 | 64 |
| Carvedilol | Carvedilol | 173 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 50 |
| Allopurinol | Allopurinol | 167 | 39 |
| Donepezil Hcl | Donepezil Hcl | 167 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 161 | 39 |
| Buspirone Hcl | Buspirone Hcl | 159 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 40 |
| Glimepiride | Glimepiride | 153 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 153 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 37 |
| Clonidine Hcl | Clonidine Hcl | 141 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 127 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 127 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 35 |
| Jardiance | Empagliflozin | 113 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 112 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 110 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 106 | 20 |
| Ozempic | Semaglutide | 102 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 31 |
| Celecoxib | Celecoxib | 98 | 25 |
| Rivastigmine | Rivastigmine Tartrate | 96 | suppressed |
| Spironolactone | Spironolactone | 91 | 18 |
| Clonazepam | Clonazepam | 90 | 15 |
| Lorazepam | Lorazepam | 86 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 84 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 21 |
| Methylprednisolone | Methylprednisolone | 83 | 75 |
| Mounjaro | Tirzepatide | 83 | 19 |
| Azithromycin | Azithromycin | 82 | 68 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 81 | 22 |
| Ondansetron Odt | Ondansetron | 81 | 37 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 79 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 78 | 29 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 78 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 21 |
| Sotalol | Sotalol Hcl | 74 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 73 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 16 |
| Valsartan | Valsartan | 71 | suppressed |
| Bumetanide | Bumetanide | 70 | 17 |
| Memantine Hcl | Memantine Hcl | 68 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 67 | suppressed |
| Levetiracetam | Levetiracetam | 66 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 64 | suppressed |
| Myrbetriq | Mirabegron | 62 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 50 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | suppressed |
| Linzess | Linaclotide | 55 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 16 |
| Irbesartan | Irbesartan | 52 | suppressed |
| Olanzapine | Olanzapine | 52 | suppressed |
| Atenolol | Atenolol | 49 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 49 | 12 |
| Glipizide Er | Glipizide | 48 | 13 |
| Fentanyl | Fentanyl | 47 | suppressed |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Prednisone | Prednisone | 45 | 15 |
| Glipizide | Glipizide | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Temazepam | Temazepam | 42 | suppressed |
| Tradjenta | Linagliptin | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Januvia | Sitagliptin Phosphate | 41 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 21 |
| Albuterol Sulfate | Albuterol Sulfate | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Baclofen | Baclofen | 38 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 25 |
| Alendronate Sodium | Alendronate Sodium | 37 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 37 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 25 |
| Synjardy | Empagliflozin/Metformin Hcl | 34 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Levofloxacin | Levofloxacin | 31 | 26 |
| Nitroglycerin | Nitroglycerin | 31 | 14 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | 11 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Novolog | Insulin Aspart | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 15 |
| Nabumetone | Nabumetone | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 21 |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 25 | suppressed |
| Roflumilast | Roflumilast | 25 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Belsomra | Suvorexant | 21 | suppressed |
| Nystatin | Nystatin | 21 | 16 |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Trimethoprim | Trimethoprim | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 15 |
| Digoxin | Digoxin | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Exelon | Rivastigmine | 11 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Moexipril Hcl | Moexipril Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $189.82 · 10 records | ABBVIE INC. | BREZTRI, CAPLYTA, Kerendia, MOUNJARO, Ozempic, QULIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error